Annals of Oncology Advance Access published online on July 27, 2006
Annals of Oncology, doi:10.1093/annonc/mdl159
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
1 Department of Biochemistry and Molecular Biology, Peking University School of Oncology, Beijing Cancer Hospital and Institute, Beijing, China
* To whom correspondence should be addressed. Background: Increasing evidence has suggested that phosphatase of regenerating liver-3 (PRL-3) plays an important role in cancer cell migration, invasion and metastasis. However, the correlation between the PRL-3 expression and clinical outcome in breast cancer has not been investigated. Patients and methods: Using a PRL-3-specific monoclonal antibody 3B6, PRL-3 expression was assessed by immunohistochemistry in tumor tissues from 382 breast cancer patients with a median follow-up of 65 months. Results: We found that 34.8% patients expressed a high level of PRL-3 protein in their tumors. Patients with a high level of PRL-3 in the tumor had a worse disease-specific survival (DSS) rate than those with a low level of PRL-3 (74.0% versus 84.9%, P = 0.011), and PRL-3 remained an independent prognostic marker for DSS (HR 1.8, 95% CI 1.1-2.9, P = 0.019) in multivariate analysis. More importantly, in 219 node-negative patients, PRL-3 showed a significant correlation with DSS in univariate analysis (P = 0.014) and retained a borderline significance (HR 2.65, 95% CI 0.92-7.64, P = 0.071) in multivariate analysis. Conclusions: Our results suggest that PRL-3 may serve as an unfavorable prognostic marker in breast cancer, especially for patients with node-negative diseases. Thus, our findings may provide useful information for individualized therapy in the clinical setting.
Received April 26, 2006
Revised May 29, 2006
Accepted May 30, 2006
original article
Overexpression of phosphatase of regenerating liver-3 in breast cancer: association with a poor clinical outcome
L. Wang 1, L. Peng 1, B. Dong 2, L. Kong 3, L. Meng 1, L. Yan 1, Y. Xie 4 *, and C. Shou 1
2 Department of Pathology, Peking University School of Oncology, Beijing Cancer Hospital and Institute, Beijing, China
3 People Hospital of Henan Province, Zhengzhou, HeNan
4 Breast Center, Peking University School of Oncology, Beijing Cancer Hospital and Institute, Beijing, China
Y. Xie, E-mail: zlxyt2{at}bjmu.edu.cn
Abstract 
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  K. GUZINSKA-USTYMOWICZ, A. PRYCZYNICZ, and A. KEMONA PTP4A3 Expression Increases Strongly in Lymph Node Metastases from Colorectal Carcinoma Anticancer Res, October 1, 2009; 29(10): 3913 - 3916. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 U.-M. Fagerli, R. U. Holt, T. Holien, T. K. Vaatsveen, F. Zhan, K. W. Egeberg, B. Barlogie, A. Waage, H. Aarset, H. Y. Dai, et al. Overexpression and involvement in migration by the metastasis-associated phosphatase PRL-3 in human myeloma cells Blood, January 15, 2008; 111(2): 806 - 815. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. Stephens, H. Han, G. Hostetter, M. J. Demeure, and D. D. Von Hoff Small interfering RNA-mediated knockdown of PRL phosphatases results in altered Akt phosphorylation and reduced clonogenicity of pancreatic cancer cells Mol. Cancer Ther., January 1, 2008; 7(1): 202 - 210. [Abstract] [Full Text] [PDF]
|
|